Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 17/20 | 0.55 |
| ▸ | ARG2 | P78540 | 14/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169865 | 1.00 | ARG1 (0.55) | ARG1ARG2HDAC1HDAC2FFAR1 | |
| SCHEMBL1740814 | 0.89 | ARG1 (0.59) | ARG1ARG2 | |
| SCHEMBL13251231 | 0.89 | ARG1 (0.64) | ARG1ARG2 | |
| SCHEMBL1740763 | 0.88 | ARG1 (0.55) | ARG1ARG2 | |
| SCHEMBL1742328 | 0.86 | ARG1 (0.61) | ARG1ARG2 | |
| SCHEMBL1740773 | 0.85 | ARG2 (0.53) | ARG1ARG2 | |
| Trifluoroacetic Acid SCHEMBL3420542 | 0.84 | ARG1 (0.59) | ARG1ARG2 | |
| SCHEMBL1742309 | 0.84 | ARG1 (0.55) | ARG1ARG2 | |
| SCHEMBL1739381 | 0.83 | ARG2 (0.54) | ARG1ARG2 | |
| SCHEMBL1742349 | 0.83 | ARG1 (0.56) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | claimed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | claimed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | claimed |
| US-10118936-B2 | Arginase inhibitors and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-11-06 | — | — | US | claimed |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2016-07-07 | — | — | US | claimed |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | US | claimed |
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | disclosed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | disclosed |
| US-10118936-B2 | Arginase inhibitors and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-11-06 | — | — | US | disclosed |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2016-07-07 | — | — | US | disclosed |
| EP-2389352-A2 | ARGINASE INHIBITORS AND METHODS OF USE | The Trustees Of The University Of Pennsylvania (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8040818-B2 | Method for exchange of upkeep-relevant information with a computer-supported, upkeep system | ENDRESS + HAUSER PROCESS SOLUTIONS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085797-A2 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885HDAC1 168/4885 |
| US-10118936-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885HDAC1 168/4885 |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885HDAC1 168/4885 |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885HDAC1 168/4885 |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885HDAC1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.